114 related articles for article (PubMed ID: 2227573)
1. Human ovarian cancers specifically bind daunorubicin-OC-125 conjugate: an immunofluorescence study.
Dezsö B; Török I; Rosik LO; Sweet F
Gynecol Oncol; 1990 Oct; 39(1):60-4. PubMed ID: 2227573
[TBL] [Abstract][Full Text] [Related]
2. Daunorubicin conjugated to a monoclonal anti-CA125 antibody selectively kills human ovarian cancer cells.
Sweet F; Rosik LO; Sommers GM; Collins JL
Gynecol Oncol; 1989 Sep; 34(3):305-11. PubMed ID: 2788601
[TBL] [Abstract][Full Text] [Related]
3. Specific binding and internalization of monoclonal antibody HI98-daunorubicin conjugate by human leukemic cells (HL60).
Liu J; Zhu Z; Liu J; Yin S; Chu Y; Qi S; Yang C; Chen Z
Chin Med Sci J; 1991 Sep; 6(3):157-9. PubMed ID: 1793879
[TBL] [Abstract][Full Text] [Related]
4. Electrophilic analogues of daunorubicin and doxorubicin.
Rosik LO; Sweet F
Bioconjug Chem; 1990; 1(4):251-6. PubMed ID: 2096917
[TBL] [Abstract][Full Text] [Related]
5. Use of CA 125 monoclonal antibody to monitor patients with ovarian cancer.
Kudlacek S; Schieder K; Kölbl H; Neunteufel W; Nowotny C; Breitenecker G; Biegelmayer G; Vetterlein M; Fürlinger B; Micksche M
Gynecol Oncol; 1989 Dec; 35(3):323-9. PubMed ID: 2480931
[TBL] [Abstract][Full Text] [Related]
6. Distribution and pharmacokinetics of the prodrug daunorubicin-GA3 in nude mice bearing human ovarian cancer xenografts.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Biochem Pharmacol; 1999 Mar; 57(6):673-80. PubMed ID: 10037453
[TBL] [Abstract][Full Text] [Related]
7. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium.
Chang K; Pastan I; Willingham MC
Int J Cancer; 1992 Feb; 50(3):373-81. PubMed ID: 1735605
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical localization of CA 125 antigen in formalin-fixed paraffin sections of ovarian tumors with the use of Pronase.
Shishi J; Ghazizadeh M; Oguro T; Aihara K; Araki T
Am J Clin Pathol; 1986 May; 85(5):595-8. PubMed ID: 3518399
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts.
Houba PH; Boven E; Erkelens CA; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Br J Cancer; 1998 Dec; 78(12):1600-6. PubMed ID: 9862570
[TBL] [Abstract][Full Text] [Related]
10. Increase of daunorubicin and vincristine accumulation in multidrug resistant human ovarian carcinoma cells by a monoclonal antibody reacting with P-glycoprotein.
Broxterman HJ; Kuiper CM; Schuurhuis GJ; Tsuruo T; Pinedo HM; Lankelma J
Biochem Pharmacol; 1988 Jun; 37(12):2389-93. PubMed ID: 2898943
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.
Molthoff CF; Pinedo HM; Schlüper HM; Nijman HW; Boven E
Br J Cancer; 1992 May; 65(5):677-83. PubMed ID: 1586596
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro binding characteristics and biodistribution in tumor-bearing athymic mice of anti-ovarian carcinoma monoclonal antibodies.
Boerman O; Massuger L; Makkink K; Thomas C; Kenemans P; Poels L
Anticancer Res; 1990; 10(5A):1289-95. PubMed ID: 2241105
[TBL] [Abstract][Full Text] [Related]
13. Comparison between serum CA 125 and CA 19-9 assays and tissular OC 125 and 1116NS 19-9 reactivity in malignant and benign ovarian tumors.
Gadducci A; Ciancia EM; Malagnino G; De Luca F; Campani D; Ferdeghini M; Facchini V; Pingitore R; Fioretti P
Eur J Gynaecol Oncol; 1992; 13(4):346-54. PubMed ID: 1516586
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies that discriminate between human ovarian carcinomas and benign ovarian tumours.
Boerman OC; Makkink WK; Thomas CM; Hanselaar AG; Yedema CA; Kenemans P; Poels LG
Eur J Cancer; 1990 Feb; 26(2):117-27. PubMed ID: 2138906
[TBL] [Abstract][Full Text] [Related]
15. Reactivity of polyclonal and two monoclonal antibodies with cell subsets isolated from cystic fluids of ovarian serous neoplasms.
Harłozińska A; Bar JK; Rabczyński J; Bast RC; Richter R; Cisło M
Tumori; 1990 Oct; 76(5):505-10. PubMed ID: 1701581
[TBL] [Abstract][Full Text] [Related]
16. Six new monoclonal antibodies to serous, mucinous, and poorly differentiated ovarian adenocarcinomas.
Mettler L; Radzun HJ; Salmassi A; Köchling W; Parwaresch MR
Cancer; 1990 Apr; 65(7):1525-32. PubMed ID: 2178766
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a rabbit heteroantiserum and a murine monoclonal antibody raised against a human epithelial ovarian carcinoma cell line.
Berkowitz R; Kabawat S; Lazarus H; Colvin R; Knapp R; Bast RC
Am J Obstet Gynecol; 1983 Jul; 146(6):607-12. PubMed ID: 6346879
[TBL] [Abstract][Full Text] [Related]
18. Development of new immunoradiometric assay for CA 125 antigen using two monoclonal antibodies produced by immunizing lung cancer cells.
Kunimatsu M; Endo K; Nakashima T; Awaji T; Saga T; Watanabe Y; Kawamura Y; Ohta H; Koizumi M; Sakahara H
Ann Nucl Med; 1988 Nov; 2(2):73-9. PubMed ID: 3275111
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometric double labeling technique for screening of multidrug resistance.
Gheuens EE; van Bockstaele DR; van der Keur M; Tanke HJ; van Oosterom AT; De Bruijn EA
Cytometry; 1991; 12(7):636-44. PubMed ID: 1685985
[TBL] [Abstract][Full Text] [Related]
20. Antibody immunoglobulin G (IgG) against human prostatic specific antigen (PSA) as a carrier protein for chemotherapeutic drugs to human prostate tumors: Part 1. A double immunofluorescence analysis.
Sinha AA; Sackrison JL; DeLeon OF; Wilson MJ; Gleason DF
Anat Rec; 1996 Aug; 245(4):652-61. PubMed ID: 8837723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
